Phaseline

Companies › Navigator Medicines

Navigator Medicines: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NAV-240–Phase 2Hidradenitis Suppurativa (HS)Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07384975NAV-240Phase 2Hidradenitis Suppurativa (HS)ImmunologySep 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. OrthoTrophix Resolve Therapeutics Elevara Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.